Transcatheter aortic valve replacement (TAVR) was first performed in 2002.1 Since then, a tremendous amount of progress with this innovative technology has resulted in widespread adoption of this procedure for treatment of aortic valve disease. More than 10 000 TAVRs were performed in the United States alone since Food and Drug Administration (FDA) approval of the first device in 2011.2 Contrary to Europe, where 10 different valves have been approved by the European Union, in the United States all except a few hundred cases have been performed using only 2 valves. These 2 distinctly different transcatheter valve systems have gone through a series of developments. However, the fundamental characteristics of the valves remain unchanged.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.